Antimicrobial Advice Ad Hoc Expert Group
HumanVeterinaryAntimicrobial resistance
The Antimicrobial Advice Ad Hoc Expert Group (AMEG) was set up to provide guidance on the the impact on public health and animal health of the use of antibiotics in animals, and on the measures to manage the possible risk to humans.
AMEG is an ad hoc group established jointly under the Committee for Veterinary Medicinal Products (CVMP) and the Committee for Medicinal Products for Human Use (CHMP)">Committee for Medicinal Products for Human Use (CHMP).
AMEG's tasks include:
- the categorisation of antimicrobials, including aminoglycosides and penicillins, based on their risk to public health due to the development of antimicrobial resistance (AMR) following use in animals. Categorisation may have a significant impact on veterinarians' selection and use of antimicrobial medicinal products, and on national treatment guidelines;
- the development of a preliminary risk profiling of antibiotics. This is intended to address the risk to public health from AMR and will be assessed prior to the submission of a marketing authorisation application. It will inform decisions on restricting or banning the use of a substance in food-producing species, and on the need to introduce risk management measures.
For more information, see Advice on impacts of using antimicrobials in animals.
Composition
The AMEG is composed of representatives and experts from EMA's CVMP and CVMP Antimicrobials Working Party, the CHMP and CHMP Infectious Diseases Working Party, the European Food Safety Authority (EFSA), the European Centre for Disease Prevention and Control (ECDC), and the Joint Interagency Antimicrobial Consumption and Resistance Analysis (JIACRA) working group.
Members
Below (in alphabetical order of surname) are the current members of the working group. The members' declarations of interests are available in the European expert list.